What is GLP-1 Hormone? Exploring Its Role in Weight Management and Diabetes

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Glucagon-like peptide-1 is an incretin hormone your gut releases in response to food. It contributes to glucose-dependent insulin secretion, slows gastric emptying and participates in appetite regulation — and the native hormone is broken down within minutes, which is why it was never a practical medicine on its own. What changed everything was engineering molecules that act at the same receptor but persist far longer. Semaglutide, the active ingredient in Ozempic and Wegovy, has an elimination half-life of approximately one week according to the Ozempic prescribing information. That single property is what made once-weekly dosing, and this entire drug class, possible.

What the Native Hormone Does

GLP-1 is secreted by enteroendocrine cells in the intestine after eating. Its best-characterized effect is potentiating insulin release from pancreatic beta cells in a glucose-dependent manner — meaning the effect scales with how high blood glucose actually is rather than firing regardless.

That glucose dependence is clinically important and shows up in how the labels handle hypoglycemia. The Ozempic label frames hypoglycemia risk primarily around concomitant use with insulin or an insulin secretagogue, reporting documented symptomatic hypoglycemia in 17.3% and 24.4% of patients when Ozempic 0.5 mg and 1 mg were coadministered with a sulfonylurea. The hormone pathway itself does not drive glucose down indiscriminately.

Gastric Emptying and Appetite

GLP-1 receptor activation slows the rate at which the stomach empties. This has two consequences that appear throughout the labeling: it contributes to reduced energy intake, and it creates drug interaction considerations because it can affect absorption of orally administered medications.

The two labels handle that interaction differently. The Ozempic injection label notes that semaglutide delays gastric emptying and may impact absorption of concomitantly administered oral medications, instructing use with caution. The Rybelsus and Ozempic tablets label goes further, directing prescribers to consider increased clinical or laboratory monitoring with other oral medications that have a narrow therapeutic index or require monitoring. The documents are not interchangeable on this point.

From Hormone to Medication

Engineered receptor agonists are structurally modified to resist rapid degradation and to bind albumin, which extends circulation time enormously. Semaglutide reaches maximum concentration one to three days post dose and achieves steady-state exposure following four to five weeks of once-weekly administration, with absolute bioavailability of 89%.

Tirzepatide adds a second mechanism: it is a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, engaging a second incretin pathway. That is a genuine pharmacological difference between the two most-discussed molecules in this space, not a marketing distinction.

The Diabetes Applications

Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

Rybelsus and Ozempic tablets cover glycemic control and cardiovascular risk reduction in adults with type 2 diabetes at high risk for those events. Mounjaro is indicated as an adjunct to diet and exercise for glycemic control in type 2 diabetes. None of these carries a weight-management indication.

The Weight Management Applications

The Wegovy label covers reducing excess body weight and maintaining weight reduction long term in adults and pediatric patients aged 12 and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity. It also carries a cardiovascular risk reduction indication and, under accelerated approval, an indication for noncirrhotic MASH with moderate to advanced fibrosis.

Zepbound is approved for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity. Foundayo (orforglipron), approved April 1, 2026, is an oral GLP-1 receptor agonist indicated for chronic weight management with a labeled limitation against concomitant use with another GLP-1 receptor agonist.

What the Pathway Does Not Do

It does not permanently reset metabolism. The STEP 1 trial extension followed 327 participants for a year after treatment and lifestyle intervention stopped; mean weight loss of 17.3% at week 68 became a net 5.6% by week 120, with cardiometabolic improvements reverting toward baseline for most variables. The authors described this as confirming the chronicity of obesity.

It also does not act in isolation from behavior. Every weight-management indication in these labels is written as applying in combination with a reduced-calorie diet and increased physical activity, and the trials delivered both alongside the drug. Understanding the hormone helps; it does not replace understanding the intervention.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What is GLP-1?

Glucagon-like peptide-1 is an incretin hormone secreted by enteroendocrine cells in the intestine in response to food. It potentiates insulin release from pancreatic beta cells in a glucose-dependent manner, slows gastric emptying and participates in appetite regulation. The native hormone is degraded within minutes, which is why engineered receptor agonists with far longer duration became the practical medicines.

Why can these medications be dosed once weekly?

Because of engineered pharmacokinetics. The Ozempic prescribing information reports that semaglutide has an elimination half-life of approximately one week, absolute bioavailability of 89%, maximum concentration reached one to three days post dose, and steady-state exposure achieved following four to five weeks of once-weekly administration. The principal protraction mechanism is albumin binding.

What does "glucose-dependent" mean in practice?

It means the insulin-releasing effect scales with prevailing blood glucose rather than acting regardless of it. That shapes how the labels handle hypoglycemia, which is framed primarily around concomitant insulin or insulin secretagogue use. The Ozempic label reports documented symptomatic hypoglycemia in 17.3% and 24.4% of patients when 0.5 mg and 1 mg were coadministered with a sulfonylurea.

How is tirzepatide different from semaglutide?

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual agonist, acting at both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor, engaging a second incretin pathway. That is a real pharmacological difference. It does not by itself establish superiority for any individual, since the products were studied in separate trials with different populations and durations.

Does the GLP-1 pathway permanently change metabolism?

The published evidence says no. In the STEP 1 trial extension, 327 participants were followed for a year after treatment and lifestyle intervention stopped. Mean weight loss of 17.3% at week 68 became a net 5.6% by week 120, with cardiometabolic improvements reverting toward baseline for most variables. The authors described the result as confirming the chronicity of obesity.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.